Zydus Lifesciences launches Nivolumab biosimilar ‘Tishtha’ in India

22 Jan 2026 Evaluate

Zydus Lifesciences has launched the world’s first biosimilar of Nivolumab in India under the brand name Tishtha to treat multiple cancers, reinforcing the company’s growing capability in advanced biologics and Immuno-Oncology. Tishtha will be available in 100 mg and 40 mg dosages priced at Rs 28,950 and Rs 13,950 respectively. The prices are around 1/4th of the reference drug. This will improve affordability and reduce the overall treatment burden for patients. The two-strength portfolio enables oncologists to optimise dosing and minimise wastage - a key driver of treatment economics in immunotherapy.

Developed and manufactured in India, Tishtha ensures long-term dependability for patients throughout their treatment journey. For patients living with cancer, sustained and predictable access to therapy is critical. By introducing Tishtha in India, the company expands access to advanced Immuno-Oncology treatment.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

883.85 7.75 (0.88%)
22-Jan-2026 16:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1374.60
Zydus Lifesciences 883.85
Lupin 2165.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×